BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Executive Summary

• Independent Data Safety Monitoring Board (DSMB) issued its fourth consecutive positive recommendation, indicating no safety concerns for BriaCell’s pivotal Phase 3 trial of Bria‑IMT™ plus a checkpoint inhibitor in metastatic breast cancer.
• The DSMB advised the study continue without any protocol modifications, reinforcing confidence in the regimen’s safety and tolerability profile.
• The trial is conducted under FDA Fast Track Designation, underscoring its significance for an unmet medical need.

Key Details

• DSMB Recommendation: Fourth consecutive positive safety recommendation; no safety concerns identified.
• Study Status: Ongoing Phase 3 pivotal trial (NCT06072612) of Bria‑IMT™ + immune checkpoint inhibitor in metastatic breast cancer patients.
• Regulatory Context: Trial operates under FDA Fast Track Designation, reflecting high unmet need.
• Frequency of DSMB Reviews: Quarterly meetings per study protocol.
• CEO Quote: “Repeated consecutive DSMB positive recommendations further strengthen our confidence in the excellent safety and tolerability profile of the BriaCell regimen.” – Dr. William V. Williams, President & CEO.

Notable Quotes

“We strongly believe in Bria‑IMT’s potential to transform cancer care and remain determined to make it a reality for patients with metastatic breast cancer who face urgent medical needs.” – Dr. William V. Williams, President & CEO.